<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480998</url>
  </required_header>
  <id_info>
    <org_study_id>IY_IFEZ_Q120</org_study_id>
    <nct_id>NCT02480998</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults</brief_title>
  <official_title>A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent
      vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in
      healthy Korean males and females 19 to &lt; 65 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial.

      During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part
      A phase will be analyzed to determine the safety and tolerability of the investigational
      product, which should include any solicited and unsolicited adverse drug reactions occurring
      for the first 7 days after vaccination and any adverse events occurring for 28 days after
      vaccination. Antibody titer test will be also performed to evaluate the efficacy
      (immunogenicity) of the investigational product. During the Part B phase, a total of 72
      subjects will be enrolled, and all safety data (including all adverse events) and
      immunogenicity data will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer &lt; 1:40</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with a pre-vaccination (Day 0) HI antibody titer &lt; 1:40 who have achieved a minimum four-fold rise in HI antibody titer post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>IL-YANG Flu Vaccine QIV 0.5mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-YANG Flu Vaccine TIV 0.5mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Flu Vaccine QIV 0.5mL</intervention_name>
    <arm_group_label>IL-YANG Flu Vaccine QIV 0.5mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Flu Vaccine TIV 0.5mL</intervention_name>
    <arm_group_label>IL-YANG Flu Vaccine TIV 0.5mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women 19 to &lt; 65 years of age at screening

          -  Body weight within ±20% of ideal body weight at screening

          -  Women of childbearing potential must have a negative serum beta-hCG at visit 2; and
             agree to use a proper contraceptive method for 1 month after vaccination (starting
             from 3 months before screening), using a medication or device that does not have any
             drug-interaction with the investigational product.

          -  Subjects with no congenital or chronic disease who were considered suitable for the
             study after screening assessments (investigator's opinion, medical history, physical
             examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days
             prior to vaccination

          -  Subjects who were given, and fully understood, the information about the study, and
             have provided voluntary written informed consent to participate in the study and to
             comply with all applicable study requirements

        Exclusion Criteria:

          -  Subject with known allergy to eggs, chicken, or any components of the investigational
             product

          -  Subjects who had received an influenza vaccine within the last 6 months prior to study
             entry

          -  Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL

          -  Subjects who have concurrent or a past history of, immune deficiency disease

          -  Subject with a history of Guillain-Barre syndrome

          -  Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant,
             who are at increased risk of serious bleeding during intramuscular injection

          -  Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis

          -  Subjects who had an acute fever with body temperature &gt; 38.0 Cº within 72 hours prior
             to administration of the investigational product or symptoms of suspected acute
             disease within 14 days prior to administration of the investigational product

          -  Subjects who had received another vaccine within 28 days before administration of the
             investigational product or are planning to receive another vaccine during the study.

          -  Subjects who had participated in another clinical trial within the 30 days before
             administration of the investigational product.

          -  Subjects who had previously received blood-derived products (including immunoglobulin)
             within the last 3 months prior to administration of the Investigational product, or
             are scheduled to receive a treatment with blood-derived products during the study

          -  Subjects who had received, or are scheduled to receive, systemic immunosuppressive
             therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior
             to administration of the study

          -  Subjects with a history of drug abuse within the last 6 months prior to vaccination,
             or is suspected of drug abuse

          -  Subjects with excessive consumption of caffeine, alcohol, or tobacco

          -  Subjects with other clinically significant medical or psychiatric illness who in the
             investigator's opinion, are not be suitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>August 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2018</results_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="P2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="B2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.77" spread="7.01"/>
                    <measurement group_id="B2" value="27.75" spread="8.48"/>
                    <measurement group_id="B3" value="27.10" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate</title>
        <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate</title>
          <description>Percentage of subjects achieving seroconversion* for HI antibody after vaccination</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.93" lower_limit="46.04" upper_limit="71.81"/>
                    <measurement group_id="O2" value="64.29" lower_limit="46.54" upper_limit="82.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.29" lower_limit="51.74" upper_limit="76.84"/>
                    <measurement group_id="O2" value="53.57" lower_limit="35.10" upper_limit="72.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.36" lower_limit="42.34" upper_limit="68.38"/>
                    <measurement group_id="O2" value="35.71" lower_limit="17.97" upper_limit="53.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.43" lower_limit="33.37" upper_limit="59.49"/>
                    <measurement group_id="O2" value="14.29" lower_limit="1.32" upper_limit="27.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate</title>
        <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
            <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate</title>
          <description>Percentage of subjects achieving seroprotection* for HI antibody after vaccination</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.64" lower_limit="88.75" upper_limit="100.00"/>
                    <measurement group_id="O2" value="85.71" lower_limit="72.75" upper_limit="98.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.43" lower_limit="91.57" upper_limit="100.00"/>
                    <measurement group_id="O2" value="82.14" lower_limit="67.96" upper_limit="96.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="78.84" upper_limit="96.16"/>
                    <measurement group_id="O2" value="78.57" lower_limit="63.37" upper_limit="93.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.57" lower_limit="67.82" upper_limit="89.32"/>
                    <measurement group_id="O2" value="64.29" lower_limit="46.54" upper_limit="82.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT</title>
        <description>Geometric Mean Titer</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR</title>
        <description>Geometric Mean Ratio</description>
        <time_frame>28 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer &lt; 1:40</title>
        <description>Percentage of subjects with a pre-vaccination (Day 0) HI antibody titer &lt; 1:40 who have achieved a minimum four-fold rise in HI antibody titer post-vaccination</description>
        <time_frame>28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IL-YANG Flu Vaccine QIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL</description>
        </group>
        <group group_id="E2">
          <title>IL-YANG Flu Vaccine TIV 0.5mL</title>
          <description>A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Dong-suck Lim, CI</name_or_title>
      <organization>The catholic university of Korea, Seoul ST. Marry's Hospital</organization>
      <phone>+82-2-2258-7327</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

